PhRMA's Senior Management Team: Industry Experience with Cajun Seasoning
This article was originally published in RPM Report
Executive Summary
The people behind the new Pharmaceutical Research & Manufacturers of America under former House Energy & Commerce Committee Chairman Billy Tauzin, and the appointees on PhRMA's independent direct-to-consumer advertising review panel.
You may also be interested in...
Pharma's Patience Pays Off: Patient Advocates Are Powerful Allies in Part D
The pharmaceutical industry has long counted on patient advocates as allies in the FDA drug approval process. But their relationship on issues related to drug coverage has often been tense. The Medicare drug benefit has opened a new chapter in the relationship. Patient advocates have worked closely with the Centers for Medicare & Medicaid Services in the early months of Part D, and they have had an impact. Industry's long-time effort to establish alliances is paying off.
Pharma's Patience Pays Off: Patient Advocates Are Powerful Allies in Part D
The pharmaceutical industry has long counted on patient advocates as allies in the FDA drug approval process. But their relationship on issues related to drug coverage has often been tense. The Medicare drug benefit has opened a new chapter in the relationship. Patient advocates have worked closely with the Centers for Medicare & Medicaid Services in the early months of Part D, and they have had an impact. Industry's long-time effort to establish alliances is paying off.
Time to Pay the Piper? Industry Prepares for a Fight Over User Fees
The pharmaceutical industry and FDA are getting ready for a fight-and for once they are on the same side. They want Congress to reauthorize the Prescription Drug User Fee Act quickly and cleanly-without tacking on other reforms to FDA's drug regulations. They probably won't get their wish.